Effective total lesion reduction:
- EVOCLIN has proven to be effective in the reduction of total, inflammatory and non-inflammatory lesions.
- Overall efficacy objectives were met or exceeded.
Effective in reduction of inflammatory and non-inflammatory lesions.2
*Results from a 12-week, double-blind, vehicle-controlled safety and efficacy study (N=1,026) designed to demonstrate the noninferiority of EVOCLIN Foam to clindamycin gel and the superiority of EVOCLIN to its foam vehicle.
EVOCLIN is a once-a-day topical clindamycin foam for the treatment of acne vulgaris.
The most common adverse events in clinical trials were headache (3%) and application-site reactions including burning (6%), itching (1%), and dryness (1%).
EVOCLIN is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, or a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Diarrhea, bloody diarrhea, and pseudomembranous colitis have been reported with systemic and rarely with topical clindamycin. Discontinuation is recommended if diarrhea develops.